80SBio AG

Revolutionizing diagnostics in developing societies

After a positive test for HIV infection, the doctor recommends another test to measure the
number of viral particles in the blood, as represented by the RNA only (called Viral titre). The blood sample of the patient has both the RNA and DNA of the HIV retrovirus.
The current RT-qPCR test used to measure the Viral RNA in blood ends up counting the viral DNA too, leading to an inflated results. This leads to systematic over drugging of patients by the doctors who depend on this data, along with higher quality-of-life restrictions on patients that have achieved non-transmissible status, increasing the costs across the healthcare value chain.
We have developed a qRT-PCR test that neglects the presence of DNA and gives precise viral titre, improving patient lives and saving costs.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

No Awards

80SBio AG

Revolutionizing diagnostics in developing societies

Headquarter:
Basel

Foundation Date:
June 2022

Technology:

  • Biotech

Sectors:

  • Biotech
  • Diagnostics
  • Research and development